WallStreetZenWallStreetZen

NASDAQ: DMAA
Drugs Made In America Acquisition Corp Earnings Dates, Reports, Calls

OverviewEarnings
RevenueDividendOwnership
Drugs Made In America Acquisition earnings were -$279.8k for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest DMAA earnings report on Dec 31, 2024 announced Q4 2024 earnings of N/A, down N/A from last quarter.

DMAA earnings history

Current Revenue
$0.0
Current Earnings
-$279.8k
Current Profit Margin
0%

DMAA Return on Equity

Insufficient data to display

DMAA undefined

Insufficient data to display

Be the first to know when DMAA announces earnings.

DMAA undefined

Current Company
114.29%
Current Industry
-2.5%

DMAA vs Shell Company Stocks

TickerEBITDAEarningsY/Y EarningsEPS
DMAA-$279.85k-$279.85kN/A-$0.03
GIG$2.38M$2.38MN/A$0.10
BACQ$1.52M$1.52MN/A$0.10
HYAC$11.32M$11.32M+22.58%$0.38
VACH$4.14M$4.14MN/A$0.26
View Top Shell Company Stocks

Drugs Made In America Acquisition Earnings Reports & History FAQ

What was DMAA's earnings growth in the past year?

As of Drugs Made In America Acquisition's earnings date in Q2 2025, Drugs Made In America Acquisition's earnings has grown year over year. DMAA earnings in the past year totalled -$279.85 thousand.

If you're new to stock investing, here's how to buy Drugs Made In America Acquisition stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.